Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future oncology Karam, I., Yao, M., Heron, D. E., Poon, I., Koyfman, S. A., Yom, S. S., Siddiqui, F., Lartigau, E., Cengiz, M., Yamazaki, H., Hara, W., Phan, J., Vargo, J. A., Lee, V., Foote, R. L., Harter, K. W., Lee, N. Y., Sahgal, A., Lo, S. S. 2017; 13 (7): 603-613

Abstract

To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer.15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors.SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%.There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.

View details for DOI 10.2217/fon-2016-0403

View details for PubMedID 27842456